Clinical Trials Logo

Clinical Trial Summary

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06389513
Study type Interventional
Source CanSino Biologics Inc.
Contact Peng Wan
Phone 022-58213600-6051
Email peng.wan@cansinotech.com
Status Not yet recruiting
Phase Phase 4
Start date June 2024
Completion date April 2025